A new non-thermal technology that targets cellular structures without affecting non-cellular dermal tissue may offer benefits for a range of dermatological concerns. A study on Pulse Biosciences’ Nano-Pulse Stimulation (NPS) technology, entitled “A Dose-Response Study of a New Novel Non-Thermal Method of Selectively Modifying Cellular Structures in Skin with Low Energy Nanosecond Electrical Stimulation,” received the 2018 American Society for Lasers in Medicine and Surgery (ASLMS) Best of Basic Science and Translational Research Award. Dermatopathologist and co-author of the winning paper David Mehregan, MD, noted that “Our dermatopathology lab analyzed over 200 biopsy samples from NPS-treated human skin and observed a pattern of unique cellular effects that spared the non-cellular dermis at most energy doses. These basic tissue findings demonstrate real promise for clinical studies of multiple future clinical applications.”
The company is currently investigating its technology in benign skin diseases, starting with seborrheic keratosis (SKs). In a clinical trial, presented by Thomas Rohrer, MD, at the 2018 ASLMS conference, application of NPS resulted in ‘clear’ or ‘nearly clear” outcomes in 82% of 174 treated lesions (58 subjects) after 106 days. The company also plans to study NPS’ utility in sebaceous hyperplasia.
“This unique mechanism of action of non-thermal NPS shows great potential for treating a range of benign and non-benign skin lesions,” said Dr. Rohrer.
